EHA26: BTK combos in CLL/SLL showing earlier line promise

Data was presented at EHA26 by both BeOne Medicines and Eli Lilly on their CLL/SLL combinations. Data was presented at EHA 2026 by both BeOne Medicines and Eli Lilly on their CLL/SLL combinations. CLL and SLL are among the most common haematological malignancies in adults. Credit: Nemes Laszlo / Shutterstock.com At the European Hematology Association (EHA) 2026 Congress, several therapies for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shown promise. BeOne Medicines’ wholly owned, all-oral combination of Beqalzi (sonrotoclax) plus Brukinsa (zanubrutinib) was investigated as a first line treatment in the Phase I/Ib BGB-11417-101 trial.…

Source: Clinical Trials Arena